Temperature-Responsive Multilayer Films of Micelle-Based Composites for Controlled Release of a Third-Generation EGFR Inhibitor

2020 ◽  
Vol 2 (2) ◽  
pp. 741-750 ◽  
Author(s):  
Li Xu ◽  
Hailong Wang ◽  
Zihan Chu ◽  
Lawrence Cai ◽  
Haifeng Shi ◽  
...  
Keyword(s):  
Controlled Release ◽  
Multilayer Films ◽  
Third Generation ◽  
Egfr Inhibitor ◽  
Temperature Responsive

scholarly journals Drug release from thin films encapsulated by a temperature-responsive hydrogel

Soft Matter ◽  
2019 ◽  
Vol 15 (8) ◽  
pp. 1853-1859 ◽  
Author(s):  
Oliver Werzer ◽  
Stephan Tumphart ◽  
Roman Keimel ◽  
Paul Christian ◽  
Anna Maria Coclite
Keyword(s):  
Thin Films ◽  
Controlled Release ◽  
Drug Release ◽  
Temperature Responsive ◽  
Temperature Controlled ◽  
Drug Polymer Interaction ◽  
Polymer Interaction

Temperature-controlled release and study on the effects of the drug–polymer interaction and pH.

scholarly journals Nisin/polyanion layer-by-layer films exhibiting different mechanisms in antimicrobial efficacy

RSC Advances ◽  
2020 ◽  
Vol 10 (17) ◽  
pp. 10329-10337 ◽  
Author(s):  
Hanan Fael ◽  
A. Levent Demirel
Keyword(s):  
Antimicrobial Activity ◽  
Controlled Release ◽  
Multilayer Films ◽  
Antimicrobial Efficacy ◽  
Layer By Layer

Polyanion–nisin multilayer films exhibit antimicrobial activity by controlled release of nisin or as stable biofilm inhibiting coatings depending on polyanion.

scholarly journals Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Tao Zhang ◽  
Rong Qu ◽  
Shingpan Chan ◽  
Mengzhen Lai ◽  
Linjiang Tong ◽  
...  
Keyword(s):  
Third Generation ◽  
Egfr Inhibitor ◽  
Combination Strategy

scholarly journals Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Tao Zhang ◽  
Rong Qu ◽  
Shingpan Chan ◽  
Mengzhen Lai ◽  
Linjiang Tong ◽  
...  
Keyword(s):  
Third Generation ◽  
Egfr Inhibitor ◽  
Combination Strategy

scholarly journals First- Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup Analysis

2021 ◽  
Author(s):  
Chen ◽  
An-Tai He . ◽  
Yi Pei .
Keyword(s):  
Clinical Practice ◽  
Lung Adenocarcinoma ◽  
Survival Time ◽  
First Generation ◽  
Response Rate ◽  
Cytotoxic Chemotherapy ◽  
Routine Clinical Practice ◽  
Third Generation ◽  
Egfr Inhibitor ◽  
Mean Survival Time

Abstract BackgroundThe third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive lung adenocarcinoma patients and more recently for first-line treatment of EGFR-mutant T790M negative lung adenocarcinoma, Similarly to previous generation TKIs, despite the high response rate, disease progression eventually occurs and current clinical research is focused on novel strategies to delay the emergence of osimertinib resistance.In this study,we investigated a the combination of osimertinib/ gefitinib/ erlotinib with cytotoxic chemotherapy for EGFR-mutated positive lung adenocarcinoma patients in long-term survival outcomes. Method We enrolled Ⅲb-IV stage lung adenocarcinoma patients with an EGFR mutation，Patients receiving standard Osimertinib,Gefitinib,Erlotinip alone treatment and Osimertinib,Gefitinib and Erlotinip with cytotoxic chemotherapy treatment were retrospectively reviewed.The performance status were collected,The response rate, progression-free survival (PFS) and overall survival (OS) and toxicity profile were analyzed.ResultBetween January 2014 to Dec 2020,240 patients with Ⅲb-Ⅳstages lung adenocarcinoma were enrolled from a institution.All patients who received different standard treatment respectively,were divided into four groups,64 who received（gefitinib or Erlotinb)with cytotoxic chemotherapy, 60 who received single gefitinib or erlotinib.58 who received (Osimertinib) with cytotoxic chemotherapy,58 who received single (Osimertinib) were eligible for this study.First generation Chemical-TKItherapy group PFS vs First generation TKI therapy alone PFS.P<0.05. Mean Survival Time 22.00 month,95%CI[16.29,27.70] VS 16.00 month.95%CI[11.98,20.01].First generation Chemical-TKItherapy group OS vs First generation TKI therapy alone OS. P<0.05. Mean Survival Time 32.00 month,95%CI[25.29,3871] VS 28.00 month, 95%CI[14.58,41.41].Third generation Chemical-TKItherapy group PFS vs Third generation TKI therapy PFS. P<0.001.Mean Survival Time 40.00,95%CI[28.12,51.87] VS 26.66 95%CI[24.77,29.22].Third generation Chemical-TKItherapy group OS vs Third generation TKI therapy OS.P<0.05. Mean Survival Time 48.00.95%CI[42.81,53.18] VS 36.00. 95%CI[34.71,38.28].First-Third generation Chemical-TKItherapy group PFS vs.First-Third generation TKI therapy alone PFS.P<0.001.Mean Survival Time 28.00,95%CI[24.86,31.11] VS 17.00 95%CI[13.83,20.16].First-Third generation Chemical-TKItherapy group OS vs First-Third generation TKI therapy alone OS.P<0.001. Mean Survival Time 41.00.95%CI[31.70,50.30] VS 29.00. 95%CI[17.68,38.31].Cox regression models showed a significant prognostic factors for OS were old age (55-69 years) (HR = 0.49 [0.28–0.89], p < 0.02) and gene mutation (Positive) (HR = 0.15 [0.07–0.29], p < 0.05),First add third generationTKI with chemicaltherapy (HR = 0.56 [0.35–0.89], p < 0.02). ConclusionFirst-Third generation EGFR inhibitor combined with cytotoxic chemotherapy represents a suitable palliative treatment option in further therapy lines for elderly patients with advanced lung adenocarcinoma.The results obtained under real-life conditions add to our understanding of the benefits and risks of First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in routine clinical practice.

Sign in / Sign up

Export Citation Format

Share Document